is semaglutide a lifelong medication Using diabetes, obesity drugs for weight loss comes with risk Pharmacokinetic properties of once-weekly subcutaneous

GLP-1/GIP dual agonists are thought to be more effective at lowering blood glucose and body weight than GLP-1s alone

Current evidence does not establish a causal relationship between GLP-1-based weight loss injections and most cancers in humans

Together, they create a more comprehensive metabolic intervention than either drug alone, which is especially valuable for patients with type 2 diabetes or significant metabolic dysfunction

Further analysis found that the products did not contain semaglutide, the medications active ingredient, raising concerns about patient exposure to ineffective or potentially unsafe substances